A First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK356278 (PDE4 Inhibitor) in Healthy Volunteers.

Trial Profile

A First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK356278 (PDE4 Inhibitor) in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs GSK 356278 (Primary)
  • Indications Anxiety disorders; Depression
  • Focus Adverse reactions
  • Acronyms FTIM
  • Most Recent Events

    • 17 Sep 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
    • 17 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top